Evidence map›Paper›PMID 29568767›Full record

ArticleBioMed research international2018

Construction and Characterization of a Recombinant Human Respiratory Syncytial Virus Encoding Enhanced Green Fluorescence Protein for Antiviral Drug Screening Assay.

Min Xu, Yue-Ying Jiao, Yuan-Hui Fu, Nan Jiang, Yuan-Bo Zheng, Yi-Fei Yan, Mei Zhang, Yan-Peng Zheng, Wu-Yang Zhu, Xiang-Lei Peng and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BioMed research international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Reporter-expressing viruses for antiviral drug discovery research.Frontiers in cellular and infection microbiology · 2025
    Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Min XuCollege of Life Sciences and Bioengineering, Beijing Jiaotong University, Beijing 100044, China.ORCID 0000-0003-0438-1368
Yue-Ying JiaoCollege of Life Sciences and Bioengineering, Beijing Jiaotong University, Beijing 100044, China.
Yuan-Hui FuCollege of Life Sciences and Bioengineering, Beijing Jiaotong University, Beijing 100044, China.
Nan JiangCollege of Life Sciences and Bioengineering, Beijing Jiaotong University, Beijing 100044, China.
Yuan-Bo ZhengCollege of Life Sciences and Bioengineering, Beijing Jiaotong University, Beijing 100044, China.
Yi-Fei YanCollege of Life Sciences and Bioengineering, Beijing Jiaotong University, Beijing 100044, China.
Mei ZhangDepartment of Immunology, Anhui Medical University, Hefei 230032, China.
Yan-Peng ZhengCollege of Life Sciences and Bioengineering, Beijing Jiaotong University, Beijing 100044, China.
Wu-Yang ZhuNational Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
Xiang-Lei PengCollege of Life Sciences and Bioengineering, Beijing Jiaotong University, Beijing 100044, China.ORCID 0000-0003-4522-5978
Jin-Sheng HeCollege of Life Sciences and Bioengineering, Beijing Jiaotong University, Beijing 100044, China.ORCID 0000-0002-6592-0540
Beijing Jiaotong University · CNAnhui Medical University · CNNational Institute for Viral Disease Control and Prevention · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human respiratory syncytial virus (RSV) is the single most important cause of lower respiratory tract disease in infants and young children and a major viral agent responsible for respiratory tract disease in immunosuppressed individuals and the elderly, but no vaccines and antiviral drugs are available. Herein the recombinant RSV (rRSV) encoding enhanced green fluorescence protein (EGFP, rRSV-EGFP) was constructed and the potential for screening anti-RSV drugs was investigated. The recombinant plasmid of pBRATm-rRSV-EGFP, containing T7 transcription cassette composed of T7 promoter, RSV antigenomic cDNA with EGFP gene, HDV ribozyme (

Indexed as

AnimalsAntiviral AgentsCell LineChlorocebus aethiopsCricetinaeFluorescenceGreen Fluorescent ProteinsHEK293 CellsHumansRecombination, GeneticRespiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsRNA, MessengerVero CellsViral ProteinsVirus ReplicationAntiviral Agentsenhanced green fluorescent proteinGreen Fluorescent ProteinsRNA, MessengerViral Proteins

Identifiers

PMID29568767
PMCPMC5820570
OpenAlexW2783357101

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.